Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries
- 5 April 2004
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 489 (1-2) , 93-100
- https://doi.org/10.1016/j.ejphar.2004.02.038
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Cilostazol (Pletal®): A Dual Inhibitor of Cyclic Nucleotide Phosphodiesterase Type 3 and Adenosine UptakeCardiovascular Drug Reviews, 2001
- CilostazolDrugs & Aging, 1999
- Identification, Characterization, and Functional Role of Phosphodiesterase Type IV in Cerebral Vessels: Effects of Selective Phosphodiesterase InhibitorsJournal of Cerebral Blood Flow & Metabolism, 1997
- Cyclic Nucleotide Phosphodiesterases and Vascular Smooth MuscleAnnual Review of Pharmacology and Toxicology, 1996
- Section Review: Cardiovascular & Renal: Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseasesExpert Opinion on Investigational Drugs, 1995
- Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscleBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1992
- Effects of isozyme‐selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levelsActa Physiologica Scandinavica, 1990
- Effects of Cilostazol, a Selective cAMP Phosphodiesterase Inhibitor on the Contraction of Vascular Smooth MusclePharmacology, 1988
- Effects of prostaglandin E1, Isoproterenol and forskolin on cyclic AMP levels and tension in rabbit aortic ringsLife Sciences, 1986
- Mechanical properties of vascular smooth muscle cells in situNature, 1976